Stock Track | Exact Sciences Stock Plummets After Disappointing Q3 Results and Lowered Guidance

Stock Track11-06

Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, experienced a significant stock plunge of 27.93% on November 6, 2024, following the release of its third-quarter 2024 financial results and lowered full-year outlook.

For the third quarter, Exact Sciences reported revenue of $709 million, an increase of 13% year-over-year, but missed analysts' expectations of $717.66 million. The company posted a net loss of $38.2 million, or $0.21 per share, slightly better than analysts' estimates of a $0.20 per share loss. However, the company's revenue and earnings fell short of expectations, contributing to the stock's sell-off.

The primary factor driving the sharp decline was Exact Sciences' lowered full-year 2024 guidance. The company reduced its revenue guidance to a range of $2.73 billion to $2.75 billion, down from its previous estimate of $2.81 billion to $2.85 billion, citing weaker-than-expected Screening revenue. Additionally, Exact Sciences cut its adjusted EBITDA outlook for the year to $310 million to $320 million, down from the prior range of $335 million to $355 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114799749?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114799749","market":"us","top_or_hot":-1,"title":"Stock Track | Exact Sciences Stock Plummets After Disappointing Q3 Results and Lowered Guidance","media":"Stock Track","content":"<p>Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, experienced a significant stock plunge of 27.93% on November 6, 2024, following the release of its third-quarter 2024 financial results and lowered full-year outlook.</p>\n\n<p>For the third quarter, Exact Sciences reported revenue of $709 million, an increase of 13% year-over-year, but missed analysts' expectations of $717.66 million. The company posted a net loss of $38.2 million, or $0.21 per share, slightly better than analysts' estimates of a $0.20 per share loss. However, the company's revenue and earnings fell short of expectations, contributing to the stock's sell-off.</p>\n\n<p>The primary factor driving the sharp decline was Exact Sciences' lowered full-year 2024 guidance. The company reduced its revenue guidance to a range of $2.73 billion to $2.75 billion, down from its previous estimate of $2.81 billion to $2.85 billion, citing weaker-than-expected Screening revenue. Additionally, Exact Sciences cut its adjusted EBITDA outlook for the year to $310 million to $320 million, down from the prior range of $335 million to $355 million.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Exact Sciences Stock Plummets After Disappointing Q3 Results and Lowered Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Exact Sciences Stock Plummets After Disappointing Q3 Results and Lowered Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 22:47 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, experienced a significant stock plunge of 27.93% on November 6, 2024, following the release of ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"","article_id":"1114799749","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114799749","pubTimestamp":1730904434,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Exact Sciences Corporation , a leading provider of cancer screening and diagnostic tests, experienced a significant stock plunge of 27.93% on November 6, 2024, following the release of its third-quarter 2024 financial results and lowered full-year outlook.For the third quarter, Exact Sciences reported revenue of $709 million, an increase of 13% year-over-year, but missed analysts' expectations of $717.66 million. The company posted a net loss of $38.2 million, or $0.21 per share, slightly better","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学"},"translate_title":"股票轨迹Exact Sciences股价在第三季度业绩令人失望并下调指引后暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":1},"content_text":"Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, experienced a significant stock plunge of 27.93% on November 6, 2024, following the release of its third-quarter 2024 financial results and lowered full-year outlook.\nFor the third quarter, Exact Sciences reported revenue of $709 million, an increase of 13% year-over-year, but missed analysts' expectations of $717.66 million. The company posted a net loss of $38.2 million, or $0.21 per share, slightly better than analysts' estimates of a $0.20 per share loss. However, the company's revenue and earnings fell short of expectations, contributing to the stock's sell-off.\nThe primary factor driving the sharp decline was Exact Sciences' lowered full-year 2024 guidance. The company reduced its revenue guidance to a range of $2.73 billion to $2.75 billion, down from its previous estimate of $2.81 billion to $2.85 billion, citing weaker-than-expected Screening revenue. Additionally, Exact Sciences cut its adjusted EBITDA outlook for the year to $310 million to $320 million, down from the prior range of $335 million to $355 million.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114799749"}